Memantine delayed N-methyl-D-aspartate -induced convulsions in neonatal rats

Fundamental and Clinical Pharmacology

Volumn 29, Issue 1, 2015, Pages 72-78

  Dhir, Ashish ^a   Chopra, Kanwaljit ^b  

^a GUJARAT FORENSIC SCIENCES UNIVERSITY   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

NMDA; Behavioral seizures; Levetiracetam; Memantine; Neonatal seizures

Indexed keywords

ETIRACETAM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; CLONUS; CONTROLLED STUDY; DRUG EFFECT; EPILEPTIC STATE; INFANTILE SPASM; MORTALITY; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; FEMALE; MALE; METABOLISM; SEIZURES; SPRAGUE DAWLEY RAT;

ANIMALS; ANIMALS, NEWBORN; DISEASE MODELS, ANIMAL; FEMALE; MALE; MEMANTINE; N-METHYLASPARTATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES;

EID: 84921029324     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12090     Document Type: Article

References (34)

1. Lai M.C., Lui C.C., Yang S.N., Wang J.Y., Huang L.T. Epileptogenesis is increased in rats with neonatal isolation and early-life seizure and ameliorated by MK-801: a long-term MRI and histological study. Pediatr. Res. (2009) 66 441-447.
2. Schoepp D.D., Gamble A.Y., Salhoff C.R., Johnson B.G., Ornstein P.L. Excitatory amino acid-induced convulsions in neonatal rats mediated by distinct receptor subtypes. Eur. J. Pharmacol. (1990) 182 421-427.
3. Stafstrom C.E., Tandon P., Hori A., Liu Z., Mikati M.A., Holmes G.L. Acute effects of MK801 on kainic acid-induced seizures in neonatal rats. Epilepsy Res. (1997) 26 335-344.
4. Haberny K.A., Paule M.G., Scallet A.C. et al. Ontogeny of the N-methyl-D-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci. (2002) 68 9-17.
5. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx (2004) 1 101-110.
6. Chen H.S., Pellegrini J.W., Aggarwal S.K. et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. (1992) 12 4427-4436.
7. Chen H., Liu Z., Zhou Z., Jiang M., Qian L., Wu S. The regulatory effect of memanine on expression and synthesis of heat shock protein 70 gene in neonatal rat models with cerebral hypoxic ischemia. Chin. Med. J. (2003) 116 558-564.
8. Pellegrini J.W., Lipton S.A. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann. Neurol. (1993) 33 403-407.
9. Manning S.M., Boll G., Fitzgerald E., Selip D.B., Volpe J.J., Jensen F.E. The clinically available NMDA receptor antagonist, memantine, exhibits relative safety in the developing rat brain. Int. J. Dev. Neurosci. (2011) 29 767-773.
10. van Marum R.J. Current and future therapy in Alzheimer's disease. Fundam. Clin. Pharmacol. (2008) 22 265-274.
11. Geter-Douglass B., Witkin J.M. Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology (1999) 146 280-289.
12. Apland J.P., Cann F.J. Anticonvulsant effects of memantine and MK-801 in guinea pig hippocampal slices. Brain Res. Bull. (1995) 37 311-316.
13. McLean M.J. In vitro electrophysiological evidence predicting anticonvulsant efficacy of memantine and flunarizine. Pol. J. Pharmacol. Pharm. (1987) 39 513-525.
14. Czuczwar S.J., Turski W.A., Kleinrok Z. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs. Metab. Brain Dis. (1996) 11 143-152.
15. Rammes G., Danysz W., Parsons C.G. Pharmacodynamics of Memantine: an update. Curr. Neuropharmacol. (2008) 6 55-78.
16. Mares P., Mikulecká A. Different effects of two N-methyl-D-aspartate receptor antagonists on seizures, spontaneous behavior, and motor performance in immature rats. Epilepsy Behav. (2009) 14 32-39.
17. Khanna A., Walcott B.P., Kahle K.T. Limitations of current GABA agonists in neonatal seizures: toward GABA modulation via the targeting of neuronal Cl(-) transport. Front Neurol. (2013) 4 78.
18. Hornick P. A new method for giving repetitive intraperitoneal injections to neonatal rats. Lab. Anim. (1986) 20 14-15.
19. Talos D.M., Chang M., Kosaras B., Murphy A., Folkerth R.D., Jensen F.E. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model. Pediatr. Res. (2013) 73 24-30.
20. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. (2003) 9 275-308.
21. Szczurowska E., Mareš P. NMDA and AMPA receptors: development and status epilepticus. Physiol. Res. (2013) 62 S21-S38.
22. Kahle K.T., Barnett S.M., Sassower K.C., Staley K.J. Decreased seizure activity in a human neonate treated with bumetanide, an inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. J. Child Neurol. (2009) 24 572-576.
23. Nunez J.L., McCarthy M.M. Evidence for an extended duration of GABA-mediated excitation in the developing male versus female hippocampus. Dev. Neurobiol. (2007) 67 1879-1890.
24. Chahal H., D'Souza S.W., Barson A.J., Slater P. Modulation by magnesium of N-methyl-D-aspartate receptors in developing human brain. Arch. Dis. Child. Fetal Neonatal Ed. (1998) 78 F116-F120.
25. Bo T., Jiang Y., Cao H., Wang J., Wu X. Long-term effects of recurrent seizures in neonatal rats on NMDA receptor expression in the brain. Beijing Da Xue Xue Bao (2003) 35 292-295.
26. Sanchez R.M., Koh S., Rio C. et al. Decreased glutamate receptor 2 expression and enhanced epileptogenesis in immature rat hippocampus after perinatal hypoxia-induced seizures. J. Neurosci. (2001) 21 8154-8163.
27. Cornejo B.J., Mesches M.H., Coultrap S., Browning M.D., Benke T.A. A single episode of neonatal seizures permanently alters glutamatergic synapses. Ann. Neurol. (2007) 61 411-426.
28. Saunders N.R., Liddelow S.A., Dziegielewska K.M. Barrier mechanisms in the developing brain. Front. Pharmacol. (2012) 3 46.
29. Cherian A., Thomas S.V. Status epilepticus. Ann. Indian Acad. Neurol. (2009) 12 140-153.
30. Boggs J.G. Mortality associated with status epilepticus. Epilepsy Curr. (2004) 4 25-27.
31. Brandt C., Potschka H., Löscher W., Ebert U. N-methyl-D-aspartate receptor blockade after status epilepticus protects against limbic brain damage but not against epilepsy in the kainate model of temporal lobe epilepsy. Neuroscience (2003) 118 727-740.
32. Fujikawa D.G., Daniels A.H., Kim J.S. The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage. Epilepsy Res. (1994) 17 207-219.
33. Kábová R., Liptáková S., Slamberová R., Pometlová M., Velísek L. Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model. Epilepsia (1999) 40 1357-1369.
34. Kojovic M., Cordivari C., Bhatia K. Myoclonic disorders: a practical approach for diagnosis and treatment. Ther. Adv. Neurol. Disord. (2011) 4 47-62.